Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Kyowa Kirin Advances Oncology Pipeline with Strategic Milestones and Corporate Realignment

Kyowa Kirin Co. Ltd. has made significant strides in its oncology and immunotherapy pipeline, with recent milestones including a $30 million payment for a menin inhibitor collaboration and a Phase III study showing a survival benefit for its mogamul…

Dr. Michael Chen

25/10/2025, 09:00

4 minutes to read

Astellas Pharma Sees Share Price Surge Following Positive Fezolinetant Trial Results and FDA Priority Review for PADCEV

Astellas Pharma Inc. has announced positive results from a Phase IV clinical trial of fezolinetant for menopausal symptoms and received FDA priority review for PADCEV in muscle-invasive bladder cancer, driving an upward trend in the company’s share …

Dr. Michael Chen

23/10/2025, 10:37

5 minutes to read

QIAGEN NV Sees Share Price Surge Amid Rate Cut Hopes and Scientific Advancements

QIAGEN NV’s share price has experienced a moderate uptick due to macro-economic optimism and reduced political risk, but its underlying value is driven by its strong scientific pipeline, diversified revenue streams, and strategic regulatory position…

Dr. Michael Chen

19/10/2025, 13:47

4 minutes to read

Merck KGaA Shares Surge Amid Regulatory Changes and Strong Pipeline Prospects

Merck KGaA’s stock price surged over 10% in a single trading session, driven by a combination of regulatory developments, market trends, and the company’s own operational outlook, including revised revenue forecasts and promising late-stage clinical…

Dr. Michael Chen

04/10/2025, 08:38

5 minutes to read

Genmab A/S Sees Market Surge Amid Strategic Merger and Scientific Breakthroughs

Genmab A/S, a Danish biotech firm, is experiencing market momentum due to its strategic acquisition of Merus and advancements in its antibody-based oncology portfolio, with analysts revising their price targets and the company’s shares surpassing a …

Dr. Michael Chen

03/10/2025, 16:59

5 minutes to read

Lonza Group AG Strengthens Biotech Partnerships Amid Stable Market Performance

Lonza Group AG, a Swiss contract development and manufacturing organization (CDMO), maintains a stable market presence, driven by its expertise in bioprocessing and strategic partnerships in emerging therapeutic areas, despite modest share price flu…

Dr. Michael Chen

30/09/2025, 11:16

4 minutes to read

U.S. Tariffs Hit Chūgai Pharmaceutical: Stock Declines Amid Rising Costs and Regulatory Challenges

The 100% tariff on imported branded pharmaceuticals announced by the US President has triggered a decline in stock prices for Japanese pharmaceutical companies, including Chūgai Pharmaceutical Co., Ltd., and poses significant economic and regulator…

Dr. Michael Chen

27/09/2025, 14:12

4 minutes to read

Revvity Inc. Partners with Profluent to Enhance Precision Genome Editing with AI

Revvity Inc. has partnered with Profluent to develop and commercialize AI-enhanced adenine deaminase-based Pin-point base editing systems, aiming to deliver precise and high-throughput genome editing capabilities for researchers and clinicians.

Dr. Michael Chen

24/09/2025, 13:26

4 minutes to read

Haleon PLC Maintains Stability with Strategic Share Repurchases Amid Market Volatility

Haleon PLC’s share price has remained relatively stable despite market volatility, thanks to strategic share repurchases and a growing global presence through its partnership with Wellnex Life.

Dr. Michael Chen

23/09/2025, 12:43

4 minutes to read

Sartorius AG’s Share Price Soars Amid Strong Financials and Strategic Positioning in Biopharmaceutical Technology

Sartorius AG’s recent share price surge is driven by strong financial performance, strategic positioning in the biopharmaceutical technology sector, and positive market sentiment, reflecting the company’s critical role in contemporary drug developme…

Dr. Michael Chen

19/09/2025, 08:44

3 minutes to read

Newer articles